Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer

被引：14

作者：

Dash, Raju ^{[1
]}

Uddin, Mir Muhammad Nasir ^{[2
]}

Hosen, S. M. Zahid ^{[3
]}

Bin Rahim, Zahed ^{[1
]}

Dinar, Abu Mansur ^{[4
]}

Kabir, Mohammad Shah Hafez ^{[5
]}

Sultan, Ramiz Ahmed ^{[2
]}

Islam, Ashekul ^{[6
]}

Hossain, Md Kamrul ^{[2
]}

机构：

[1] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4000, Bangladesh

[2] Univ Chittagong, Dept Pharm, Chittagong 4331, Bangladesh

[3] BCSIR, Pharmacol Res Div, MMDDL, Chittagong 4220, Bangladesh

[4] Sq Pharmaceut Ltd, Qual Control Operat, Dhaka, Bangladesh

[5] Int Islamic Univ Chittagong, Dept Pharm, Chittagong 4203, Bangladesh

[6] Univ Chittagong, Dept Biochem & Mol Biol, Chittagong 4331, Bangladesh

来源：

BIOINFORMATION | 2015年 / 11卷 / 12期

关键词：

COX-2; FlexX; ArgusLab; Flavonoids; Cancer;

D O I：

10.6026/97320630011543

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Cydooxygenase-2 (COX-2) catalyzed synthesis of prostaglandin E2 and it associates with tumor growth, infiltration, and metastasis in preclinical experiments. Known inhibitors against COX-2 exhibit toxicity. Therefore, it is of interest to screen natural compounds like flavanoids against COX-2. Molmular docking using 12 known flavanoids against COX-2 by FlexX and of ArgusLab were performed. All compounds showed a favourable binding energy of >-10 KJ/mol in FlexX and > -8 kcal/mol in ArgusLab. However, this data requires in vitro and in vivo verification for further consideration.

引用

页码：543 / 549

页数：7

共 50 条

[41] SAR: Flavonoids and COX-2 inhibition
Rosenkranz, HS
Thampatty, BP
ONCOLOGY RESEARCH, 2003, 13 (12) : 529 - 535
[42] The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors
Wang, Z
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) : 1771 - 1777
[43] Comparative molecular field analysis of selective cyclooxygenase-2 (COX-2) inhibitors
Marot, C
Chavatte, P
Lesieur, D
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 2000, 19 (02): : 127 - 134
[44] The molecular basis of COX-2 versus COX-1 selectivity of lumiracoxib by molecular docking studies
Correa, Celia M.
de Paula, Andre F.
da Silva, Gilberto M. S.
Sant'Anna, Carlos M. R.
Fraga, Carlos A. M.
Barreiro, Eliezer J.
LETTERS IN DRUG DESIGN & DISCOVERY, 2007, 4 (06) : 422 - 425
[45] COX-2 inhibitors: cancer prevention or cardiovascular risk?
Senior, K
LANCET ONCOLOGY, 2005, 6 (02): : 68 - 68
[46] COX-2 inhibitors still eyed for cancer prevention
Thompson, CA
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (09) : 890 - +
[47] RTOG Symposium COX-2 Inhibitors and Cancer Therapeutics
Dicker, AP
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : S45 - S45
[48] COX-2 inhibitors and prevention of colon cancer.
Dannenberg, AJ
CLINICAL CANCER RESEARCH, 2000, 6 : 4480S - 4480S
[49] Molecular docking analysis of UniProtKB nitrate reductase enzyme with known natural flavonoids
Shaik, Ayub
Thumma, Vishnu
Kotha, Aruna Kumari
Kramadhati, Sandhya
Pochampally, Jalapathy
Bandi, Seshagiri
BIOINFORMATION, 2016, 12 (12) : 425 - 429
[50] Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells
Agarwal, B
Swaroop, P
Protiva, P
Raj, SV
Shirin, H
Holt, PR
APOPTOSIS, 2003, 8 (06) : 649 - 654

← 1 2 3 4 5 →